Roth Capital analyst David Solomon downgraded Obalon Therapeutics (NASDAQ: OBLN) from Buy to Neutral with a price target of $2.75 ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE